Jynarque - (15 mg, 30 mg, 45 mg, 60 mg, 90 mg Tablet)

Generic Name	Tolvaptan	Innovator	Otsuka
Dosage	15 mg, 30 mg, 45 mg, 60 mg, 90 mg Tablet	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	JYNARQUE is a selective vasopressin V2-receptor antagonist indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****	***\ ***	*** **, ****	*** ** ** / ******* ** **	********* ********	** *** **, **** (***)
****	** \ **	**** **, ****	*******	****	******* *** **** (***) *** *** ****
******	** \ **	*** **, ****	*******	****	******* *** **** *** *** ****

Chronology Of Events